Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine
Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
Vistagen to Present at the Jefferies Global Healthcare Conference
Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Vistagen Reports Fiscal 2024 Third Quarter Financial Results